LOGIN  |  REGISTER
Assertio

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 445.93
1.29 0.29
752,095
253.72M
US$ 113.140B
US$ 746.80
20.59 2.84
849,824
103.28M
US$ 77.130B
US$ 889.49
-0.62 -0.07
229,810
61.57M
US$ 54.770B
US$ 412.63
8.17 2.02
1.66M
132.11M
US$ 54.510B
US$ 195.24
5.39 2.84
1.78M
213.27M
US$ 41.640B
US$ 96.00
0.26 0.27
889,128
240.46M
US$ 23.080B
US$ 488.51
3.65 0.75
213,882
43.06M
US$ 21.040B
US$ 32.30
1.06 3.39
2.33M
615.99M
US$ 19.900B
US$ 96.10
0.93 0.98
983,670
196.32M
US$ 18.870B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 38.81
0.55 1.44
3.80M
427.25M
US$ 16.580B
US$ 154.75
-0.88 -0.57
669,363
99.71M
US$ 15.430B
US$ 78.51
0.63 0.81
2.15M
193.32M
US$ 15.180B
US$ 21.34
1.10 5.43
28.24M
695.49M
US$ 14.840B
US$ 74.07
1.36 1.87
1.11M
192.71M
US$ 14.270B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 17.99
0.05 0.28
1.58M
744.44M
US$ 13.390B
US$ 571.33
18.86 3.41
269,985
22.71M
US$ 12.970B
US$ 210.16
8.92 4.43
1.97M
61.10M
US$ 12.840B
US$ 79.14
0.51 0.65
1.56M
161.97M
US$ 12.820B
US$ 29.63
0.60 2.07
9.50M
390.73M
US$ 11.580B
US$ 41.39
0.32 0.78
2.53M
268.11M
US$ 11.100B
US$ 71.60
0.25 0.35
1.51M
150.68M
US$ 10.790B
US$ 29.99
0.51 1.73
968
349.00M
US$ 10.470B
US$ 133.09
5.56 4.36
2.63M
77.90M
US$ 10.370B
US$ 52.99
-0.71 -1.32
1.06M
192.11M
US$ 10.180B
US$ 164.89
-0.08 -0.05
588,727
60.77M
US$ 10.020B
US$ 70.82
1.95 2.83
1.92M
135.81M
US$ 9.620B
US$ 60.26
-0.57 -0.94
1.38M
155.81M
US$ 9.390B
US$ 87.13
1.82 2.13
702,257
105.19M
US$ 9.170B
US$ 106.91
0.00 0.00
0
84.98M
US$ 9.090B
US$ 129.46
0.00 0.00
0
64.58M
US$ 8.360B
US$ 117.62
12.85 12.26
3.41M
66.74M
US$ 7.850B
US$ 148.75
-0.52 -0.35
160,740
50.41M
US$ 7.500B
US$ 26.54
-0.56 -2.07
1.90M
282.15M
US$ 7.490B
US$ 60.77
0.45 0.75
1.43M
122.26M
US$ 7.430B
US$ 96.63
-0.14 -0.14
1.44M
75.85M
US$ 7.330B
US$ 61.90
-0.75 -1.20
8.21M
117.60M
US$ 7.280B
US$ 246.78
7.06 2.95
188,372
29.00M
US$ 7.160B
US$ 105.91
0.17 0.16
219,618
67.27M
US$ 7.120B
US$ 220.19
0.59 0.27
477,597
31.45M
US$ 6.920B
US$ 267.28
5.70 2.18
408,139
25.01M
US$ 6.680B
US$ 87.81
-2.08 -2.31
1.73M
71.95M
US$ 6.320B
US$ 40.04
0.87 2.22
2.57M
153.51M
US$ 6.150B
US$ 44.59
1.10 2.53
1.02M
130.91M
US$ 5.840B
US$ 92.25
0.87 0.95
577,665
62.52M
US$ 5.770B
US$ 150.24
3.25 2.21
697,938
37.51M
US$ 5.640B
US$ 58.09
0.50 0.87
1.02M
95.30M
US$ 5.540B
US$ 36.00
-0.14 -0.39
2.40M
145.68M
US$ 5.240B
US$ 32.00
1.40 4.58
1.42M
158.76M
US$ 5.080B
US$ 20.38
0.40 2.00
1.82M
238.00M
US$ 4.850B
US$ 29.17
0.55 1.92
1.63M
165.12M
US$ 4.820B
US$ 49.31
1.25 2.60
531,547
94.89M
US$ 4.680B
US$ 100.77
-1.06 -1.04
574,672
46.27M
US$ 4.660B
US$ 44.60
-0.45 -1.00
1.57M
102.01M
US$ 4.550B
US$ 26.68
-0.13 -0.48
672,546
169.18M
US$ 4.510B
US$ 54.65
0.00 0.00
0
82.32M
US$ 4.500B
US$ 24.81
1.25 5.31
14.40M
175.28M
US$ 4.350B
US$ 23.01
-0.35 -1.50
1.31M
184.69M
US$ 4.250B
US$ 72.69
0.71 0.99
855,477
57.82M
US$ 4.200B
US$ 76.53
0.47 0.62
618,012
54.83M
US$ 4.200B
US$ 36.17
0.56 1.57
860,156
113.39M
US$ 4.100B
US$ 67.44
-1.50 -2.18
2.26M
60.68M
US$ 4.090B
US$ 27.18
-2.39 -8.08
14.45M
146.08M
US$ 3.970B
US$ 29.47
-0.30 -1.01
1.75M
122.49M
US$ 3.610B
US$ 183.13
-0.90 -0.49
144,777
19.68M
US$ 3.600B
US$ 46.99
0.00 0.00
0
75.35M
US$ 3.540B
US$ 93.60
0.75 0.81
268,965
37.75M
US$ 3.530B
US$ 36.20
0.20 0.56
1.30M
96.48M
US$ 3.490B
US$ 81.70
0.38 0.47
220,895
42.45M
US$ 3.470B
US$ 65.72
1.05 1.62
679,577
51.39M
US$ 3.380B
US$ 43.66
0.22 0.51
932,332
77.28M
US$ 3.370B
US$ 41.61
-0.13 -0.31
330,003
80.67M
US$ 3.360B
US$ 42.22
-1.11 -2.56
600,998
79.05M
US$ 3.340B
US$ 24.97
0.29 1.18
2.61M
126.53M
US$ 3.160B
US$ 14.67
-0.74 -4.80
2.28M
213.05M
US$ 3.130B
US$ 35.01
0.63 1.83
1.21M
89.47M
US$ 3.130B
US$ 32.57
-0.03 -0.09
824,134
95.37M
US$ 3.110B
US$ 25.14
-0.26 -1.02
923,650
123.73M
US$ 3.110B
US$ 9.90
0.05 0.51
3.31M
308.53M
US$ 3.050B
US$ 33.56
-0.08 -0.24
512,826
87.67M
US$ 2.940B
US$ 45.98
1.64 3.70
1.43M
63.93M
US$ 2.940B
US$ 36.05
-0.15 -0.41
1.36M
79.14M
US$ 2.850B
US$ 32.59
-0.09 -0.28
620,245
87.00M
US$ 2.840B
US$ 8.27
0.43 5.48
7.00M
341.83M
US$ 2.830B
US$ 22.94
0.14 0.61
1.21M
122.91M
US$ 2.820B
US$ 16.76
-3.47 -17.15
40.79M
167.18M
US$ 2.800B
US$ 27.51
0.11 0.40
1.20M
101.47M
US$ 2.790B
US$ 19.42
-0.27 -1.37
5.82M
142.82M
US$ 2.770B
US$ 34.36
-0.30 -0.87
634,109
77.59M
US$ 2.670B
US$ 49.49
-0.51 -1.02
2.05M
53.71M
US$ 2.660B
US$ 17.37
-0.20 -1.14
2.54M
146.66M
US$ 2.550B
US$ 31.58
0.90 2.93
3.78M
80.16M
US$ 2.530B
US$ 23.43
-0.31 -1.31
831,749
105.87M
US$ 2.480B
US$ 18.40
-0.65 -3.41
127,540
128.29M
US$ 2.360B
US$ 15.42
-0.32 -2.03
3.91M
152.67M
US$ 2.350B
US$ 39.59
0.32 0.81
281,481
57.60M
US$ 2.280B
US$ 21.75
-0.45 -2.03
7.15M
104.79M
US$ 2.280B
US$ 14.89
0.00 0.00
0
148.49M
US$ 2.210B
US$ 2.19
-0.11 -4.78
7.83M
984.97M
US$ 2.160B
US$ 32.57
0.24 0.74
74,068
65.90M
US$ 2.150B
US$ 15.88
0.41 2.65
1.01M
131.84M
US$ 2.090B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 24.04
0.22 0.92
711,554
85.15M
US$ 2.050B
US$ 17.82
-0.46 -2.52
418,536
110.59M
US$ 1.970B
US$ 19.07
-0.54 -2.75
1.01M
101.37M
US$ 1.930B
US$ 33.09
-1.06 -3.10
782,503
57.12M
US$ 1.890B
US$ 37.39
-0.26 -0.69
207,473
50.57M
US$ 1.890B
US$ 24.94
-0.94 -3.63
520,606
74.84M
US$ 1.870B
US$ 27.94
-0.25 -0.89
605,774
66.45M
US$ 1.860B
US$ 35.80
-0.23 -0.64
217,134
50.53M
US$ 1.810B
US$ 19.49
-0.81 -3.99
944,784
91.71M
US$ 1.790B
US$ 5.75
0.22 3.98
1.40M
311.60M
US$ 1.790B
US$ 41.63
-1.95 -4.47
584,742
42.88M
US$ 1.790B
US$ 5.81
-0.04 -0.68
4.61M
307.07M
US$ 1.780B
US$ 20.41
-0.21 -1.02
1.65M
86.91M
US$ 1.770B
US$ 13.17
-0.98 -6.93
2.66M
128.23M
US$ 1.690B
US$ 4.42
0.09 2.08
3.14M
363.19M
US$ 1.610B
US$ 27.46
-0.54 -1.93
928,346
58.31M
US$ 1.600B
US$ 7.58
-0.08 -1.04
2.37M
210.54M
US$ 1.600B
US$ 5.76
0.20 3.60
5.99M
273.92M
US$ 1.580B
US$ 23.98
0.30 1.27
149,829
64.96M
US$ 1.560B
US$ 20.62
0.00 0.00
491,457
74.77M
US$ 1.540B
US$ 11.44
0.84 7.92
3.31M
132.69M
US$ 1.520B
US$ 27.47
-1.20 -4.19
578,503
54.04M
US$ 1.480B
US$ 13.07
-0.16 -1.21
1.19M
109.82M
US$ 1.440B
US$ 15.55
0.41 2.71
2.87M
92.40M
US$ 1.440B
US$ 5.90
-0.02 -0.34
2.81M
242.97M
US$ 1.430B
US$ 6.94
0.25 3.74
1.64M
203.47M
US$ 1.410B
US$ 28.78
0.11 0.38
160,374
47.66M
US$ 1.370B
US$ 7.79
0.20 2.64
1.28M
173.32M
US$ 1.350B
US$ 16.10
-0.62 -3.71
1.19M
82.79M
US$ 1.330B
US$ 5.00
0.06 1.21
6.26M
266.37M
US$ 1.330B
US$ 10.86
-0.04 -0.37
1.03M
117.42M
US$ 1.280B
US$ 24.13
-0.43 -1.75
454,049
53.05M
US$ 1.280B
US$ 3.62
0.11 3.13
1.36M
353.82M
US$ 1.280B
US$ 28.43
-0.39 -1.35
747,082
44.90M
US$ 1.280B
US$ 45.78
0.83 1.85
230,705
27.69M
US$ 1.270B
US$ 27.18
-1.49 -5.20
2.29M
45.72M
US$ 1.240B
US$ 19.75
-0.39 -1.94
3.28M
62.29M
US$ 1.230B
US$ 47.98
0.00 0.00
0
25.69M
US$ 1.230B
US$ 9.10
-0.07 -0.76
1.39M
134.68M
US$ 1.230B
US$ 10.04
-0.02 -0.20
592,871
121.56M
US$ 1.220B
US$ 12.59
0.21 1.70
1.09M
97.22M
US$ 1.220B
US$ 22.81
0.52 2.33
444,731
53.37M
US$ 1.220B
US$ 17.06
-0.10 -0.58
281,244
71.41M
US$ 1.220B
US$ 17.73
0.25 1.43
15,988
68.51M
US$ 1.210B
US$ 20.88
0.25 1.21
30,459
57.81M
US$ 1.210B
US$ 82.21
-2.30 -2.72
81,394
14.54M
US$ 1.200B
US$ 26.21
0.57 2.22
166,983
44.77M
US$ 1.170B
US$ 7.01
0.07 1.01
2.02M
165.92M
US$ 1.160B
US$ 5.12
0.01 0.20
605,280
225.17M
US$ 1.150B
US$ 17.40
0.17 0.99
412,809
65.12M
US$ 1.130B
US$ 11.61
-0.50 -4.13
1.56M
97.21M
US$ 1.130B
US$ 3.74
-0.03 -0.80
2.66M
299.34M
US$ 1.120B
US$ 23.24
0.70 3.11
51,384
48.22M
US$ 1.120B
US$ 9.55
0.18 1.92
3.54M
115.83M
US$ 1.110B
US$ 11.22
0.78 7.47
2.34M
98.85M
US$ 1.110B
US$ 18.77
-1.40 -6.94
1.67M
59.35M
US$ 1.110B
US$ 6.69
-0.05 -0.74
4.42M
162.50M
US$ 1.090B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 22.36
0.17 0.77
343,285
46.81M
US$ 1.050B
US$ 51.12
-6.62 -11.47
743,709
20.34M
US$ 1.040B
US$ 14.57
0.02 0.14
300,189
71.14M
US$ 1.040B
US$ 18.85
-0.26 -1.36
229,243
54.78M
US$ 1.030B
US$ 15.55
0.00 0.00
0
64.53M
US$ 1.000B
US$ 24.32
-0.03 -0.12
234,476
41.28M
US$ 1.000B
US$ 14.07
-0.54 -3.70
1.98M
70.85M
US$ 996.860M
US$ 11.13
0.00 0.00
0
89.31M
US$ 994.020M
US$ 35.28
-1.34 -3.66
181,529
27.71M
US$ 977.610M
US$ 4.08
0.25 6.53
15.29M
237.07M
US$ 967.250M
US$ 3.38
0.12 3.68
4.39M
283.71M
US$ 958.940M
US$ 9.69
-0.31 -3.10
452,063
97.39M
US$ 943.710M
US$ 6.70
0.15 2.29
1.04M
139.13M
US$ 932.730M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 11.74
0.25 2.18
6.17M
78.79M
US$ 924.990M
US$ 15.36
-0.22 -1.41
1.31M
60.15M
US$ 923.900M
US$ 10.46
-0.28 -2.61
1.87M
87.02M
US$ 910.230M
US$ 4.67
0.08 1.74
1.23M
192.32M
US$ 898.130M
US$ 17.68
0.07 0.40
476,145
50.67M
US$ 895.850M
US$ 2.25
-0.01 -0.44
27.55M
396.97M
US$ 893.180M
US$ 1.39
0.11 8.59
17.04M
638.36M
US$ 887.320M
US$ 8.42
-0.09 -1.06
864,312
102.68M
US$ 864.570M
US$ 4.49
0.01 0.22
187,255
191.02M
US$ 857.680M
US$ 13.80
-0.41 -2.89
457,871
62.03M
US$ 856.010M
US$ 16.90
0.04 0.24
1.46M
50.55M
US$ 854.290M
US$ 3.62
0.13 3.72
6.90M
231.46M
US$ 837.890M
US$ 9.28
0.01 0.11
956,771
88.80M
US$ 824.060M
US$ 12.57
-0.41 -3.16
666,751
64.22M
US$ 807.250M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 19.30
-0.70 -3.50
837,323
40.13M
US$ 774.510M
US$ 9.87
0.05 0.51
1.81M
78.44M
US$ 774.200M
US$ 6.32
0.09 1.44
892,819
122.00M
US$ 771.040M
US$ 4.27
-0.06 -1.39
2.64M
180.51M
US$ 770.780M
US$ 8.95
0.07 0.79
12,316
85.92M
US$ 768.980M
US$ 24.50
-0.54 -2.16
1.01M
31.29M
US$ 766.600M
US$ 42.05
0.83 2.01
290,599
18.15M
US$ 763.210M
US$ 7.87
-0.59 -6.97
36,318
96.33M
US$ 758.120M
US$ 10.59
-0.65 -5.78
2.14M
70.90M
US$ 750.830M
US$ 5.00
0.10 2.04
3.07M
149.06M
US$ 745.300M
US$ 12.38
-0.08 -0.64
1.04M
59.08M
US$ 731.410M
US$ 17.16
0.00 0.00
0
41.89M
US$ 718.830M
US$ 9.80
0.07 0.72
446,237
72.99M
US$ 715.300M
US$ 9.43
-0.58 -5.79
1.40M
75.32M
US$ 710.270M
US$ 33.41
2.13 6.81
63,069
21.22M
US$ 708.960M
US$ 8.72
0.33 3.93
441,365
80.49M
US$ 701.870M
US$ 12.80
-1.00 -7.25
2.86M
54.12M
US$ 692.740M
US$ 4.06
0.16 4.10
2.05M
169.44M
US$ 687.930M
US$ 21.69
-0.15 -0.69
455,610
30.47M
US$ 660.890M
US$ 12.85
-0.21 -1.61
1.49M
50.62M
US$ 650.470M
US$ 89.01
4.62 5.47
142,853
7.09M
US$ 631.080M
US$ 8.40
-0.09 -1.06
1.15M
74.68M
US$ 627.310M
US$ 10.92
0.09 0.83
449,242
57.14M
US$ 623.970M
US$ 8.50
-0.19 -2.19
1.01M
71.36M
US$ 606.560M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 3.41
0.00 0.00
0
171.00M
US$ 583.110M
US$ 3.84
-0.13 -3.27
3.45M
150.37M
US$ 577.420M
US$ 35.88
0.01 0.03
42,076
15.82M
US$ 567.620M
US$ 8.16
0.00 0.00
0
69.23M
US$ 564.920M
US$ 5.33
-0.10 -1.84
2.60M
104.34M
US$ 556.130M
US$ 10.33
0.46 4.66
480,293
53.83M
US$ 556.060M
US$ 2.38
-0.13 -5.18
3.68M
233.12M
US$ 554.830M
US$ 8.68
0.00 0.00
0
62.78M
US$ 544.930M
US$ 3.71
-0.02 -0.54
1.41M
145.02M
US$ 538.020M
US$ 4.64
0.00 0.00
0
115.27M
US$ 534.850M
US$ 9.24
-0.18 -1.91
204,619
56.96M
US$ 526.310M
US$ 4.18
0.17 4.24
1.10M
123.88M
US$ 517.820M
US$ 77.05
-1.17 -1.50
81,884
6.68M
US$ 514.690M
US$ 9.34
-0.01 -0.11
259,652
52.08M
US$ 486.430M
US$ 9.90
0.12 1.23
950,415
48.52M
US$ 480.350M
US$ 1.32
0.00 0.00
2.06M
363.40M
US$ 479.690M
C$ 6.05
0.19 3.24
233,162
78.34M
C$ 473.960M
US$ 8.39
-0.06 -0.71
767,013
56.30M
US$ 472.360M
US$ 6.52
0.34 5.50
279,539
71.61M
US$ 466.900M
US$ 5.87
-0.01 -0.17
439,843
77.91M
US$ 457.330M
US$ 12.75
0.07 0.55
368,113
35.86M
US$ 457.220M
US$ 16.88
0.47 2.86
154,333
26.82M
US$ 452.720M
C$ 8.86
0.17 1.96
197,595
50.65M
C$ 448.760M
US$ 10.15
0.00 0.00
0
44.21M
US$ 448.730M
US$ 1.66
0.03 1.84
9.39M
265.37M
US$ 440.510M
US$ 12.96
0.15 1.17
262,639
33.86M
US$ 438.830M
US$ 1.59
0.06 3.92
5.52M
266.14M
US$ 423.160M
US$ 4.96
-0.10 -1.98
289,302
85.26M
US$ 422.890M
US$ 6.51
0.04 0.62
146,823
63.50M
US$ 413.380M
US$ 10.81
0.22 2.08
147,558
38.22M
US$ 413.160M
US$ 2.15
0.26 13.76
4.71M
192.09M
US$ 412.990M
US$ 16.91
0.10 0.59
528
24.17M
US$ 408.710M
US$ 14.14
-0.23 -1.60
92,132
28.85M
US$ 407.940M
US$ 1.30
0.07 5.69
13.63M
312.32M
US$ 406.020M
US$ 6.20
0.04 0.65
620,145
64.57M
US$ 400.330M
US$ 14.68
0.40 2.80
226,805
26.97M
US$ 395.920M
US$ 5.74
-0.11 -1.88
234,132
68.75M
US$ 394.620M
US$ 1.71
-0.03 -1.72
640,948
230.33M
US$ 393.860M
US$ 8.60
0.00 0.00
0
45.44M
US$ 390.780M
US$ 6.60
-0.15 -2.22
1.49M
59.10M
US$ 390.060M
US$ 2.63
0.13 5.20
922,206
147.19M
US$ 387.110M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 5.22
0.09 1.75
205,712
72.33M
US$ 377.560M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 8.05
0.00 0.00
0
46.67M
US$ 375.690M
US$ 3.45
-0.18 -4.96
3.52M
108.22M
US$ 373.360M
US$ 7.43
-0.07 -0.93
210,453
49.93M
US$ 370.980M
US$ 5.71
0.22 4.01
1.73M
64.47M
US$ 368.120M
US$ 4.26
0.00 0.00
0
86.32M
US$ 367.720M
US$ 4.11
0.03 0.74
1.18M
89.35M
US$ 367.230M
US$ 8.36
0.18 2.20
218,536
43.80M
US$ 366.170M
US$ 3.36
0.09 2.75
2.99M
108.35M
US$ 364.060M
US$ 0.23
-0.0007 -0.30
854,538
1.54B
US$ 358.820M
US$ 2.25
-0.06 -2.60
4.80M
159.13M
US$ 358.040M
US$ 6.47
0.67 11.55
3.78M
54.90M
US$ 355.200M
US$ 2.81
0.39 16.12
1.69M
126.01M
US$ 354.090M
US$ 19.51
-0.44 -2.21
135,794
18.13M
US$ 353.720M
US$ 2.07
-0.02 -0.96
685,113
169.94M
US$ 351.780M
US$ 1.55
0.07 4.73
9.72M
224.73M
US$ 348.330M
US$ 4.02
0.08 2.03
2.05M
85.59M
US$ 344.070M
US$ 3.88
-0.01 -0.26
827,209
87.44M
US$ 339.270M
US$ 21.26
0.50 2.41
67,194
15.49M
US$ 329.320M
US$ 2.21
0.11 5.24
15.90M
149.00M
US$ 329.290M
US$ 26.54
-7.82 -22.76
213,899
12.38M
US$ 328.570M
US$ 2.34
0.00 0.00
3.22M
137.04M
US$ 320.670M
US$ 3.15
0.36 12.90
121.41M
100.60M
US$ 316.890M
US$ 2.22
0.05 2.30
593,683
141.55M
US$ 314.240M
US$ 6.28
0.31 5.19
1.01M
49.89M
US$ 313.310M
US$ 2.16
0.16 8.00
1.31M
143.96M
US$ 310.950M
US$ 4.19
-0.23 -5.20
2.02M
73.33M
US$ 307.250M
US$ 5.67
0.00 0.00
0
53.68M
US$ 304.370M
US$ 13.07
0.55 4.39
76,698
23.10M
US$ 301.920M
US$ 14.48
0.23 1.61
45,451
20.79M
US$ 301.040M
US$ 5.52
0.05 0.91
3.04M
54.19M
US$ 299.130M
US$ 5.73
0.14 2.50
205,980
50.39M
US$ 288.730M
US$ 2.02
0.06 3.06
16.22M
142.44M
US$ 287.730M
US$ 22.65
2.35 11.58
45,520
12.53M
US$ 283.800M
US$ 4.59
-0.20 -4.18
2.47M
60.16M
US$ 276.130M
US$ 4.41
0.12 2.80
572,399
62.26M
US$ 274.570M
US$ 12.16
1.83 17.72
4.33M
21.91M
US$ 266.430M
US$ 5.00
0.00 0.00
0
53.23M
US$ 266.150M
US$ 4.00
0.00 0.00
0
64.56M
US$ 258.240M
US$ 4.57
-0.10 -2.14
138,230
56.46M
US$ 258.020M
US$ 3.96
0.24 6.45
779,673
65.02M
US$ 257.480M
US$ 7.49
0.05 0.67
42,907
34.15M
US$ 255.780M
US$ 4.48
0.03 0.67
117,755
56.55M
US$ 253.340M
US$ 2.96
0.29 10.86
11.28M
85.17M
US$ 252.100M
US$ 1.37
0.00 0.00
5.73M
183.36M
US$ 251.200M
US$ 1.98
-0.05 -2.46
184,741
126.31M
US$ 250.090M
US$ 2.56
-0.04 -1.54
7.42M
97.62M
US$ 249.910M
US$ 4.69
0.08 1.74
315,702
53.23M
US$ 249.650M
US$ 3.19
0.03 0.95
227,600
78.13M
US$ 249.230M
US$ 2.36
0.13 5.83
1.93M
105.35M
US$ 248.630M
US$ 1.32
0.05 3.94
11.82M
187.27M
US$ 247.200M
US$ 19.26
0.09 0.47
54,628
12.82M
US$ 246.910M
US$ 4.41
-0.01 -0.23
336,856
55.60M
US$ 245.200M
US$ 4.40
0.40 10.00
3.78M
55.68M
US$ 244.990M
US$ 4.85
0.00 0.00
0
50.00M
US$ 242.500M
US$ 6.01
0.27 4.70
1.92M
38.59M
US$ 231.930M
US$ 19.63
-0.12 -0.61
207,348
11.78M
US$ 231.240M
US$ 2.27
0.00 0.00
0
100.95M
US$ 229.160M
US$ 1.37
-0.03 -2.14
6.71M
166.51M
US$ 228.120M
US$ 0.96
0.003 0.31
1.93M
236.29M
US$ 227.550M
US$ 2.36
-0.06 -2.48
1.33M
96.27M
US$ 227.200M
US$ 8.45
0.60 7.64
151,944
26.00M
US$ 219.700M
US$ 4.47
0.00 0.00
0
48.36M
US$ 216.170M
US$ 7.52
-0.15 -1.96
411,094
28.41M
US$ 213.640M
US$ 5.77
0.10 1.76
18,894
36.41M
US$ 210.090M
US$ 23.90
-0.04 -0.17
128,626
8.57M
US$ 204.820M
US$ 3.23
0.00 0.00
1.15M
63.28M
US$ 204.390M
US$ 1.72
-0.08 -4.44
112,376
118.82M
US$ 204.370M
US$ 6.33
0.01 0.16
334,763
31.00M
US$ 196.230M
US$ 7.58
0.19 2.57
117,486
25.61M
US$ 194.120M
US$ 1.53
0.05 3.04
395,633
121.27M
US$ 184.940M
US$ 1.91
0.06 3.24
3,589
92.18M
US$ 176.060M
US$ 1.86
-0.04 -2.11
2.32M
93.47M
US$ 173.850M
US$ 1.43
0.10 7.52
2.23M
120.87M
US$ 172.840M
US$ 7.42
-0.18 -2.37
366,826
23.24M
US$ 172.440M
US$ 9.70
-0.56 -5.46
2.49M
17.55M
US$ 170.240M
US$ 4.48
0.20 4.67
1,323
37.40M
US$ 167.550M
US$ 4.40
-0.11 -2.44
63,968
38.05M
US$ 167.420M
US$ 2.48
0.03 1.02
1.73M
67.36M
US$ 166.720M
C$ 2.13
-0.19 -8.19
5,811
76.38M
C$ 162.690M
US$ 4.91
-0.22 -4.31
932,893
32.92M
US$ 161.600M
US$ 1.46
0.16 12.31
16.55M
109.15M
US$ 159.360M
US$ 4.11
-0.07 -1.67
2.25M
38.46M
US$ 158.070M
US$ 2.75
0.08 3.00
1.06M
56.97M
US$ 156.670M
US$ 11.27
1.16 11.47
298,192
13.85M
US$ 156.090M
US$ 3.95
-0.58 -12.80
3.55M
39.50M
US$ 156.020M
US$ 17.16
0.18 1.06
36,650
9.05M
US$ 155.300M
US$ 0.46
-0.02 -4.68
13.42M
336.49M
US$ 154.790M
US$ 1.71
-0.11 -6.04
946,810
90.32M
US$ 154.450M
US$ 3.15
-0.11 -3.37
915,668
48.31M
US$ 152.180M
US$ 1.60
-0.03 -1.84
103,872
93.54M
US$ 149.660M
US$ 1.83
0.03 1.67
566,719
80.42M
US$ 147.170M
US$ 2.13
-0.04 -1.84
1.12M
68.70M
US$ 146.330M
US$ 1.49
-0.07 -4.49
3.24M
97.54M
US$ 145.330M
US$ 21.99
0.00 0.00
0
6.60M
US$ 145.130M
US$ 8.37
0.32 3.98
135,767
17.26M
US$ 144.470M
US$ 1.62
-0.07 -4.14
1.25M
88.27M
US$ 143.000M
US$ 28.23
0.12 0.43
43,258
5.00M
US$ 141.150M
US$ 13.08
0.28 2.19
57,388
10.73M
US$ 140.350M
US$ 4.08
-0.01 -0.24
196,307
34.01M
US$ 138.760M
US$ 6.41
-0.18 -2.73
662,781
21.49M
US$ 137.750M
US$ 9.49
-0.15 -1.56
66,265
14.42M
US$ 136.850M
US$ 2.43
0.08 3.40
130,994
55.90M
US$ 135.840M
US$ 34.10
-0.31 -0.90
7,070
3.94M
US$ 134.350M
US$ 1.87
-0.02 -1.06
796,338
71.03M
US$ 132.830M
US$ 1.43
-9.51 -86.93
604.28M
92.73M
US$ 132.600M
US$ 2.35
0.02 0.86
192,904
56.34M
US$ 132.400M
US$ 6.25
0.16 2.63
233,078
20.92M
US$ 130.750M
US$ 17.82
0.99 5.88
74,877
7.21M
US$ 128.480M
US$ 1.11
0.02 1.83
3.98M
115.35M
US$ 128.040M
US$ 1.70
0.00 0.00
1.23M
75.03M
US$ 127.550M
US$ 5.83
-0.15 -2.51
274,921
21.74M
US$ 126.740M
C$ 0.67
-0.03 -4.29
156,545
185.51M
C$ 124.290M
US$ 6.01
0.29 5.07
225,158
20.16M
US$ 121.160M
US$ 3.04
0.14 4.66
1.42M
39.80M
US$ 120.790M
US$ 7.00
0.52 8.02
819,997
17.05M
US$ 119.350M
US$ 1.96
0.06 3.16
148,907
60.57M
US$ 118.720M
US$ 4.92
-0.09 -1.80
193,172
24.07M
US$ 118.420M
US$ 42.30
0.00 0.00
10,182
2.79M
US$ 118.020M
US$ 1.65
0.02 1.23
5.12M
71.21M
US$ 117.500M
US$ 0.90
0.05 5.88
17.98M
129.17M
US$ 116.250M
US$ 1.52
-0.02 -1.30
2.68M
70.70M
US$ 107.460M
US$ 1.00
0.0084 0.85
1.05M
106.15M
US$ 105.940M
US$ 2.09
0.00 0.00
0
50.13M
US$ 104.770M
US$ 1.45
0.03 2.11
273,081
72.25M
US$ 104.760M
US$ 2.15
0.00 0.00
0
48.08M
US$ 103.370M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 2.21
0.09 4.25
43,928
45.86M
US$ 101.350M
US$ 3.79
-0.41 -9.76
1.48M
26.50M
US$ 100.440M
US$ 0.72
0.05 7.11
26.02M
137.43M
US$ 98.950M
C$ 1.18
-0.20 -14.49
658,628
83.41M
C$ 98.420M
US$ 4.36
0.00 0.00
0
22.08M
US$ 96.270M
US$ 1.04
-0.03 -2.80
1.13M
91.88M
US$ 95.560M
US$ 88.41
2.74 3.20
84,330
1.07M
US$ 94.600M
US$ 1.81
-0.02 -1.09
192,878
51.76M
US$ 93.690M
US$ 2.24
0.09 4.19
19,157
41.08M
US$ 92.020M
US$ 2.14
-0.01 -0.47
3.84M
42.99M
US$ 92.000M
US$ 2.94
0.00 0.00
157,234
31.04M
US$ 91.260M
US$ 2.18
0.16 7.92
64,318
41.12M
US$ 89.640M
US$ 1.41
0.01 0.71
1.60M
63.26M
US$ 89.200M
US$ 1.93
0.00 0.00
0
46.15M
US$ 89.070M
US$ 2.00
-0.09 -4.31
4.77M
44.42M
US$ 88.840M
US$ 2.53
-0.16 -5.95
1.29M
35.04M
US$ 88.650M
US$ 0.37
-0.005 -1.35
443,914
240.06M
US$ 87.620M
US$ 6.30
0.14 2.27
3,856
13.79M
US$ 86.880M
C$ 1.25
-0.03 -2.34
94,762
66.93M
C$ 83.660M
US$ 9.81
0.81 9.00
59,379
8.52M
US$ 83.580M
US$ 1.76
-0.05 -2.54
46,342
47.13M
US$ 83.140M
US$ 1.52
-0.02 -1.30
85,989
54.22M
US$ 82.410M
US$ 2.61
-0.01 -0.38
263,873
31.56M
US$ 82.370M
US$ 1.34
0.27 25.23
1.81M
60.89M
US$ 81.590M
US$ 1.63
-0.02 -1.21
272,603
50.02M
US$ 81.530M
US$ 1.32
0.04 3.12
809,202
61.45M
US$ 81.110M
US$ 0.52
-0.03 -5.78
34.65M
153.26M
US$ 79.240M
US$ 0.66
-0.03 -3.95
8.75M
120.28M
US$ 78.900M
US$ 8.30
0.06 0.73
204,309
9.49M
US$ 78.770M
US$ 0.68
-0.05 -6.99
8.58M
115.06M
US$ 78.130M
US$ 2.55
-0.01 -0.39
117,643
30.49M
US$ 77.750M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 3.14
0.07 2.28
143,439
24.54M
US$ 77.060M
US$ 0.78
-0.04 -4.41
4.01M
97.99M
US$ 76.430M
US$ 8.19
-0.48 -5.54
23,123
9.25M
US$ 75.760M
US$ 7.90
0.07 0.89
704,965
9.42M
US$ 74.420M
US$ 10.96
-0.43 -3.78
28,042
6.78M
US$ 74.310M
US$ 1.51
0.00 0.00
41,483
49.05M
US$ 74.070M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 2.03
0.04 2.01
482,828
35.21M
US$ 71.480M
US$ 6.88
0.20 2.99
182,870
10.33M
US$ 71.070M
US$ 1.04
-0.01 -1.05
556,746
67.75M
US$ 70.390M
US$ 1.84
-0.24 -11.54
229,548
37.77M
US$ 69.500M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 1.25
-0.01 -0.79
135,294
53.21M
US$ 66.510M
US$ 3.98
-0.03 -0.75
28,843
16.63M
US$ 66.190M
US$ 4.59
0.03 0.66
186,255
14.41M
US$ 66.140M
US$ 1.74
-0.08 -4.40
421,162
37.55M
US$ 65.340M
US$ 3.42
0.07 2.09
3,830
18.13M
US$ 62.000M
US$ 2.20
-0.01 -0.45
731,640
28.10M
US$ 61.820M
C$ 0.68
-0.01 -1.45
4,001
90.68M
C$ 61.660M
US$ 11.51
0.18 1.59
35,192
5.35M
US$ 61.580M
US$ 9.85
0.03 0.31
113,380
6.24M
US$ 61.460M
US$ 0.85
0.04 4.94
706,406
71.95M
US$ 61.160M
US$ 4.97
0.08 1.64
62,848
12.02M
US$ 59.740M
US$ 1.61
0.23 16.67
3.31M
37.03M
US$ 59.620M
US$ 12.55
-0.19 -1.49
12,196
4.69M
US$ 58.860M
US$ 2.14
-0.09 -4.04
526,585
26.59M
US$ 56.900M
US$ 2.50
-0.31 -11.03
23.05M
22.49M
US$ 56.220M
US$ 1.07
0.04 3.88
419,719
52.47M
US$ 56.140M
C$ 0.49
0.02 3.16
4,520
113.01M
C$ 55.370M
US$ 1.01
-0.01 -0.98
1.05M
54.72M
US$ 55.270M
US$ 6.07
0.20 3.41
34,201
9.05M
US$ 54.930M
US$ 2.25
0.02 0.90
75,532
24.30M
US$ 54.680M
US$ 6.45
0.08 1.26
62,021
8.34M
US$ 53.790M
US$ 0.88
0.00 0.00
0
60.97M
US$ 53.650M
US$ 1.09
0.02 1.87
543,774
48.54M
US$ 52.910M
C$ 0.08
0.005 7.14
245,000
701.73M
C$ 52.630M
US$ 6.48
-0.05 -0.77
42,991
7.99M
US$ 51.780M
US$ 0.59
0.0004 0.07
2.39M
87.41M
US$ 51.750M
US$ 1.84
-0.01 -0.54
945,747
27.98M
US$ 51.480M
US$ 1.48
0.07 4.96
713,647
34.38M
US$ 50.880M
C$ 1.84
-0.13 -6.60
111,074
27.42M
C$ 50.450M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
US$ 4.97
0.00 0.00
0
9.79M
US$ 48.660M
US$ 3.36
-0.03 -0.88
30,065
14.13M
US$ 47.480M
US$ 1.67
-0.12 -6.70
43,590
28.32M
US$ 47.290M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 1.27
0.00 0.00
0
36.59M
US$ 46.470M
US$ 6.31
-0.04 -0.63
14,358
7.32M
US$ 46.190M
US$ 29.01
-0.44 -1.49
286,697
1.59M
US$ 46.130M
US$ 0.78
0.0093 1.20
1.61M
58.79M
US$ 46.030M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
C$ 0.84
0.02 2.44
61,600
54.73M
C$ 45.970M
US$ 1.74
0.00 0.00
0
26.31M
US$ 45.780M
US$ 2.07
-0.12 -5.48
482,674
21.87M
US$ 45.270M
US$ 1.45
0.03 2.11
87,369
31.20M
US$ 45.240M
C$ 0.14
-0.01 -6.90
38,000
328.69M
C$ 44.370M
US$ 3.35
0.00 0.00
0
12.59M
US$ 42.180M
US$ 3.74
-0.08 -2.09
41,445
11.18M
US$ 41.810M
US$ 3.23
-0.24 -6.92
129,551
12.86M
US$ 41.540M
US$ 1.54
0.05 3.36
274,863
26.29M
US$ 40.490M
US$ 0.09
0.00 0.00
0
442.60M
US$ 40.280M
US$ 1.28
0.08 6.67
44,737
31.24M
US$ 39.990M
US$ 6.19
0.87 16.35
1.05M
6.37M
US$ 39.430M
US$ 1.65
-0.10 -5.71
87,133
23.43M
US$ 38.660M
US$ 11.39
-0.30 -2.57
16,112
3.39M
US$ 38.610M
US$ 9.84
-0.77 -7.26
61,990
3.82M
US$ 37.590M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 1.42
-0.07 -4.70
5.17M
26.29M
US$ 37.330M
US$ 0.71
-0.0081 -1.13
1.88M
52.50M
US$ 37.280M
US$ 1.15
0.01 0.88
88,908
32.06M
US$ 36.870M
US$ 0.99
0.02 1.65
311,839
36.65M
US$ 36.390M
US$ 5.39
-0.12 -2.18
45,044
6.74M
US$ 36.330M
US$ 9.50
0.00 0.00
809
3.81M
US$ 36.200M
US$ 0.60
0.05 9.09
8.54M
60.06M
US$ 36.040M
US$ 16.71
-1.12 -6.28
20,821
2.14M
US$ 35.760M
US$ 2.04
0.00 0.00
0
17.34M
US$ 35.370M
US$ 8.70
-0.12 -1.36
8,909
4.05M
US$ 35.240M
C$ 0.25
0.02 6.38
118,873
140.26M
C$ 35.060M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 10.68
0.19 1.81
29,720
3.18M
US$ 33.960M
US$ 3.14
-0.07 -2.18
12,009
10.66M
US$ 33.470M
US$ 0.92
-0.07 -6.67
295,526
36.19M
US$ 33.440M
C$ 0.12
0.00 0.00
38,500
287.34M
C$ 33.040M
US$ 1.92
-0.08 -4.00
200
17.17M
US$ 32.970M
US$ 1.42
0.00 0.00
0
23.18M
US$ 32.920M
C$ 0.19
0.00 0.00
0
165.94M
C$ 31.530M
US$ 0.74
-0.03 -3.64
186,593
42.24M
US$ 31.340M
US$ 0.22
-0.003 -1.36
10.65M
144.30M
US$ 31.310M
C$ 0.59
0.00 0.00
0
51.84M
C$ 30.590M
US$ 0.33
-0.01 -4.09
772,297
92.87M
US$ 30.460M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 0.33
0.00 0.00
0
90.38M
US$ 29.740M
US$ 0.72
0.02 2.27
193,663
40.83M
US$ 29.400M
US$ 3.09
-0.45 -12.71
85,402
9.25M
US$ 28.580M
US$ 4.08
0.17 4.35
61,573
6.99M
US$ 28.520M
US$ 4.18
0.23 5.82
148,778
6.76M
US$ 28.260M
US$ 2.09
0.10 5.03
416,601
13.48M
US$ 28.170M
US$ 1.23
0.07 6.03
407,501
22.23M
US$ 27.340M
US$ 0.89
0.02 1.71
652,797
29.70M
US$ 26.430M
US$ 0.63
0.00 0.00
0
41.21M
US$ 25.840M
US$ 1.15
-0.01 -0.86
67,181
22.39M
US$ 25.750M
US$ 1.12
-0.04 -3.45
487,109
22.40M
US$ 25.090M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 1.90
0.09 4.97
30,465
12.78M
US$ 24.280M
US$ 1.30
-0.02 -1.52
294,044
18.00M
US$ 23.400M
US$ 2.28
0.00 0.00
84,095
10.19M
US$ 23.230M
US$ 11.00
-0.11 -0.99
156,495
2.08M
US$ 22.880M
US$ 0.47
0.009 1.96
593,870
48.05M
US$ 22.540M
US$ 0.37
0.00 0.00
0
59.25M
US$ 21.630M
US$ 1.19
-0.01 -0.83
27,935
18.06M
US$ 21.490M
US$ 1.16
-0.01 -0.85
347,179
18.47M
US$ 21.430M
US$ 3.98
-0.23 -5.46
480,168
5.38M
US$ 21.410M
US$ 0.35
0.02 4.91
1.80M
61.29M
US$ 21.330M
C$ 0.16
0.00 0.00
0
132.87M
C$ 20.590M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 40.21
1.11 2.84
161,094
505,798
US$ 20.340M
US$ 1.67
0.11 7.05
34,228
11.73M
US$ 19.590M
US$ 1.16
-0.04 -3.33
2.15M
16.85M
US$ 19.550M
US$ 10.31
-1.00 -8.84
83,927
1.88M
US$ 19.380M
US$ 8.76
-0.34 -3.74
13,362
2.15M
US$ 18.820M
US$ 1.21
0.00 0.00
81,902
15.51M
US$ 18.770M
US$ 2.30
-0.17 -6.88
159,450
7.99M
US$ 18.380M
US$ 1.42
-0.03 -2.07
263,474
12.94M
US$ 18.370M
US$ 2.04
-0.02 -0.97
21,381
8.82M
US$ 17.990M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
C$ 0.10
0.005 5.56
276,654
188.49M
C$ 17.910M
US$ 3.18
-0.12 -3.64
17,891
5.55M
US$ 17.650M
US$ 1.15
-0.02 -1.54
72,245
14.52M
US$ 16.730M
US$ 1.29
-0.01 -0.77
87,743
12.93M
US$ 16.680M
US$ 1.63
0.03 1.88
403,828
10.09M
US$ 16.450M
US$ 3.78
-0.24 -5.97
40,119
4.24M
US$ 16.030M
US$ 1.48
0.01 0.68
67,513
10.61M
US$ 15.700M
US$ 3.16
0.01 0.32
38,778
4.93M
US$ 15.580M
US$ 3.95
-0.01 -0.25
11,620
3.94M
US$ 15.560M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 0.27
-0.0049 -1.77
2.66M
56.64M
US$ 15.410M
C$ 0.03
-0.005 -16.67
12,050
586.81M
C$ 14.670M
US$ 0.41
0.03 7.87
594,391
35.74M
US$ 14.650M
US$ 1.06
-0.01 -0.93
29,742
13.78M
US$ 14.610M
US$ 0.05
0.00 0.00
0
265.05M
US$ 14.550M
US$ 2.36
-0.11 -4.45
54,734
6.16M
US$ 14.540M
US$ 8.54
0.00 0.00
0
1.70M
US$ 14.520M
US$ 0.94
0.08 9.63
39,561
15.49M
US$ 14.480M
US$ 3.96
0.01 0.25
2,970
3.65M
US$ 14.450M
US$ 3.23
-0.08 -2.42
14,943
4.35M
US$ 14.050M
US$ 0.41
0.001 0.25
2.16M
33.29M
US$ 13.480M
US$ 1.77
0.01 0.57
44,649
7.34M
US$ 12.990M
US$ 1.10
0.02 1.85
25,694
11.70M
US$ 12.870M
US$ 12.23
1.10 9.88
315,851
1.04M
US$ 12.720M
US$ 4.13
-0.05 -1.20
22,873
3.07M
US$ 12.680M
C$ 0.12
0.00 0.00
38,370
108.62M
C$ 12.490M
US$ 0.63
-0.0002 -0.03
153,957
19.85M
US$ 12.450M
US$ 1.14
-0.03 -2.56
103,448
10.76M
US$ 12.270M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 1.48
0.20 15.62
103,535
7.85M
US$ 11.620M
US$ 0.39
-0.0078 -1.97
1.46M
29.71M
US$ 11.530M
US$ 1.52
-0.06 -3.80
21,936
7.54M
US$ 11.460M
US$ 9.00
0.43 5.02
24,640
1.26M
US$ 11.340M
US$ 5.86
5.30 946.43
7,846
1.92M
US$ 11.250M
US$ 2.20
0.04 1.85
34,951
4.81M
US$ 10.580M
US$ 1.47
-0.03 -2.00
54,319
7.17M
US$ 10.540M
C$ 0.12
-0.005 -4.17
500
91.02M
C$ 10.470M
US$ 0.81
-0.03 -3.57
96,369
12.85M
US$ 10.410M
US$ 5.00
0.17 3.52
330,593
2.07M
US$ 10.350M
C$ 0.13
0.00 0.00
0
76.57M
C$ 9.950M
US$ 1.10
0.00 0.00
13,158
8.88M
US$ 9.770M
C$ 0.13
0.00 0.00
0
74.76M
C$ 9.720M
US$ 10.42
1.79 20.74
56,285
916,968
US$ 9.550M
US$ 11.36
-0.56 -4.70
32,746
838,977
US$ 9.530M
US$ 0.20
0.00 0.00
0
47.31M
US$ 9.520M
US$ 4.27
-0.04 -0.93
48,113
2.23M
US$ 9.520M
US$ 2.95
-0.07 -2.32
31,296
3.13M
US$ 9.230M
C$ 0.06
0.005 9.09
10,000
151.90M
C$ 9.110M
US$ 1.30
0.00 0.00
0
6.83M
US$ 8.880M
US$ 0.76
-0.005 -0.65
138,489
11.64M
US$ 8.850M
US$ 2.72
0.00 0.00
0
3.18M
US$ 8.650M
US$ 4.11
-0.18 -4.20
33,318
2.09M
US$ 8.590M
C$ 0.16
0.00 0.00
16,000
52.95M
C$ 8.470M
US$ 1.33
-0.02 -1.48
14,250
6.35M
US$ 8.450M
US$ 2.18
0.02 0.93
41,470
3.80M
US$ 8.280M
US$ 0.36
0.00 0.00
0
23.14M
US$ 8.210M
US$ 1.73
-0.04 -2.26
33,848
4.63M
US$ 8.010M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 2.14
0.02 0.94
28,103
3.68M
US$ 7.880M
US$ 1.22
-0.03 -2.40
28,870
6.45M
US$ 7.870M
US$ 0.23
0.01 5.19
1.12M
33.74M
US$ 7.860M
US$ 4.05
-0.22 -5.15
71,835
1.91M
US$ 7.740M
US$ 0.82
-0.0037 -0.45
76.39M
9.03M
US$ 7.420M
US$ 1.05
-0.07 -6.25
326,757
6.95M
US$ 7.300M
US$ 0.30
-0.01 -3.91
102,110
23.99M
US$ 7.130M
US$ 4.00
-0.03 -0.74
5,432
1.77M
US$ 7.080M
US$ 1.02
-0.02 -1.92
1.85M
6.80M
US$ 6.940M
US$ 0.65
-0.02 -3.35
2.29M
10.64M
US$ 6.920M
US$ 1.15
0.06 5.50
280,899
5.92M
US$ 6.810M
US$ 3.70
-0.07 -1.86
8,973
1.83M
US$ 6.770M
C$ 3.30
0.05 1.54
485
2.04M
C$ 6.730M
C$ 0.04
0.005 14.29
422,000
166.23M
C$ 6.650M
C$ 0.02
0.00 0.00
15,000
432.32M
C$ 6.480M
US$ 1.68
-0.04 -2.33
33,034
3.81M
US$ 6.400M
US$ 0.56
0.00 0.00
2,569
11.03M
US$ 6.180M
US$ 4.61
0.00 0.00
0
1.33M
US$ 6.120M
US$ 2.84
0.00 0.00
0
2.12M
US$ 6.020M
US$ 0.95
0.04 4.14
74,847
6.31M
US$ 5.990M
US$ 0.07
0.0019 2.92
17,275
88.99M
US$ 5.960M
US$ 0.45
0.006 1.36
56,403
13.32M
US$ 5.940M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 0.70
-0.07 -9.21
5.58M
8.21M
US$ 5.740M
US$ 2.21
0.02 0.91
55,559
2.58M
US$ 5.700M
US$ 0.02
-0.001 -5.56
35,139
332.96M
US$ 5.660M
US$ 1.03
-0.03 -2.83
124,835
5.48M
US$ 5.640M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 2.42
-0.05 -2.02
34,943
2.29M
US$ 5.540M
US$ 1.42
0.09 6.77
302,116
3.74M
US$ 5.310M
US$ 1.38
-0.21 -13.21
73,132
3.84M
US$ 5.300M
US$ 3.24
-0.09 -2.70
111,842
1.63M
US$ 5.280M
US$ 0.82
0.03 3.80
37,741
6.41M
US$ 5.260M
US$ 1.42
-0.16 -10.13
334,719
3.63M
US$ 5.150M
US$ 0.29
-0.02 -6.77
757,846
17.07M
US$ 4.930M
US$ 0.81
-0.06 -6.68
887,825
5.86M
US$ 4.750M
US$ 0.91
0.00 0.00
0
5.17M
US$ 4.700M
US$ 0.34
0.00 0.00
0
13.54M
US$ 4.560M
US$ 2.57
-0.08 -3.02
6,731
1.75M
US$ 4.500M
US$ 1.05
0.00 0.00
0
4.25M
US$ 4.460M
US$ 7.65
0.12 1.59
12,739
574,580
US$ 4.400M
US$ 0.61
0.0009 0.15
18,233
6.96M
US$ 4.250M
US$ 1.97
-0.03 -1.50
39,106
2.15M
US$ 4.240M
US$ 6.68
-0.04 -0.60
1.72M
619,523
US$ 4.140M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 1.20
-0.02 -1.64
20,145
3.33M
US$ 4.000M
US$ 1.23
0.00 0.00
5,342
3.19M
US$ 3.920M
US$ 0.37
-0.02 -4.70
260,455
10.74M
US$ 3.920M
US$ 1.39
0.07 5.30
223,642
2.80M
US$ 3.890M
US$ 0.93
-0.04 -3.81
14,229
4.17M
US$ 3.880M
US$ 1.92
0.02 1.05
54,614
2.02M
US$ 3.880M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 0.87
-0.07 -7.02
322,857
4.23M
US$ 3.700M
US$ 2.31
-0.49 -17.50
73,260
1.56M
US$ 3.600M
US$ 5.33
-5.00 -48.40
1.54M
596,978
US$ 3.180M
US$ 0.07
-0.04 -37.01
10.70M
43.99M
US$ 3.170M
C$ 0.01
0.00 0.00
5,000
312.86M
C$ 3.130M
US$ 1.58
-0.10 -5.95
41,527
1.93M
US$ 3.050M
US$ 0.44
-0.05 -9.41
663,510
6.54M
US$ 2.900M
US$ 2.75
-0.15 -5.17
33,034
1.03M
US$ 2.830M
US$ 0.38
0.00 0.00
0
7.24M
US$ 2.750M
US$ 1.70
-0.12 -6.59
200
1.61M
US$ 2.740M
C$ 0.08
0.00 0.00
0
34.26M
C$ 2.740M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.02
0.00 0.00
0
124.38M
US$ 2.490M
C$ 0.02
-0.005 -20.00
476,780
121.27M
C$ 2.430M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
C$ 0.03
0.00 0.00
0
75.74M
C$ 2.270M
C$ 0.11
-0.02 -12.50
40,110
21.15M
C$ 2.220M
US$ 0.06
0.0068 12.32
38,898
33.71M
US$ 2.090M
US$ 0.65
-0.0003 -0.05
1,001
3.18M
US$ 2.070M
US$ 0.05
-0.0056 -10.26
282,053
41.85M
US$ 2.050M
US$ 0.39
0.00 0.00
0
5.23M
US$ 2.040M
US$ 0.02
-0.0002 -0.83
100
75.46M
US$ 1.810M
US$ 0.10
0.00 0.00
0
17.21M
US$ 1.800M
US$ 0.31
0.00 0.00
215
4.62M
US$ 1.430M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.09
0.00 0.00
0
16.39M
US$ 1.390M
US$ 2.33
-0.22 -8.63
232,207
559,444
US$ 1.300M
C$ 0.09
0.00 0.00
0
13.86M
C$ 1.250M
US$ 2.16
0.14 6.93
2.12M
578,625
US$ 1.250M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.14
-0.003 -2.17
3,349
8.10M
US$ 1.090M
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.07
-0.01 -16.25
1,002
11.62M
US$ 779K
US$ 0.09
0.02 26.76
1,622
8.31M
US$ 748K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.02
0.00 0.00
0
29.49M
US$ 678K
US$ 0.001
0.00 0.00
0
635.87M
US$ 636K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.008
0.00 0.00
0
39.74M
US$ 318K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.001
0.00 0.00
0
232.37M
US$ 232K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.13
0.00 0.00
0
1.24M
US$ 164K
US$ 0.02
0.00 0.00
0
4.85M
US$ 97K
US$ 0.005
0.00 0.00
0
5.23M
US$ 26K
US$ 0.02
0.00 0.00
0
1.24M
US$ 26K
US$ 0.01
0.00 0.00
0
863,788
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
0.00 0.00
0
125.63M
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
261.79M
US$ -
US$ 0.53
-0.68 -56.20
56.48M
-
US$ -
C$ 2.60
0.00 0.00
0
-
C$ -
US$ 1.50
-0.03 -1.96
911,711
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest Biotechnology Stock News


Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029   COPENHAGEN, Denmark / Dec 12, 2025 / Business Wire / Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II... Read more


Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. ... Read more


Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

SAN DIEGO / Dec 11, 2025 / Business Wire / Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share. In addition, Contineum has... Read more


Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a significant milestone in the development of a first-in-class single-dose, oral antibiotic against gonorrhea, including infections caused by drug-resistant Neisseria gonorrhoeae, an urgent public health threat and high-priority pathogen. Gonorrhea is the second most reported bacterial... Read more


Mesoblast: Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) was presented at the 67th ASH Annual meeting in Florida this past week. The independent study authors... Read more


Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development Combination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patients SAN JOSE, Calif., Dec. 11, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),... Read more


Cycle Pharmaceuticals to Acquire Applied Therapeutics

Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced a definitive agreement for Cycle Group Holdings Limited (“Cycle”)... Read more



Crinetics Pharmaceuticals Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed... Read more


Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

SAN DIEGO / Dec 11, 2025 / Business Wire / Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A common stock. In addition, Contineum intends to grant the underwriters a 30-day option... Read more


Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares sold and issued upon the full exercise... Read more


Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced it has received official notification from the U.S. Food and Drug Administration (FDA)... Read more


Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya... Read more


Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and 10.0 months with gedatolisib + fulvestrant (“gedatolisib doublet”) versus 1.9 months for fulvestrant For patients enrolled in the U.S., Canada, Western Europe, and Asia Pacific, median PFS was 16.6 months with the gedatolisib triplet and 7.1 months... Read more


Personalis: New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

FREMONT, Calif. / Dec 11, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, in the journal Cell. The study, titled "Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction," demonstrates the clinical importance of ultrasensitive, tumor-informed... Read more


MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first patient has been dosed in the Company’s THIO-104... Read more


OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group These findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal pain Corneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma... Read more


RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic Data MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared dr... Read more


Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Ra’anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced new results from its ongoing preclinical evaluation of its proprietary intranasal naloxone hydrogel formulation, demonstrating promising permeation kinetics that complement the Company’s previously reported stability and mucoadhesion successes. Following... Read more


TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform. The PRE-I-SPY program will incorporate TTX-MC138 in a Phase 2a dose-expansion clinical trial enrolling up to 45 patients with colorectal cancer who have completed... Read more


Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041  Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI Delivered Via PARI’s Proprietary eFlow® Nebulizer System  LANGHORNE, Pa. / Dec 11, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the... Read more


Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds. Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics... Read more


Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from four presentations, including two oral presentations,... Read more


Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval SEATTLE, Dec. 11, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") has... Read more


60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

6-month commercial pilot demonstrated increasing demand among prescribers Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign Additional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company’s breakthrough therapy designation request WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW)... Read more


Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy 87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapy The induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more... Read more


Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration by demonstrating that it prolongs anagen, stimulates keratin synthesis, and modulates the stem cell niche Full dataset will be presented during today’s ABS-201 Key Opinion Leader (KOL) seminar VANCOUVER,... Read more


Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the successful completion of the planned discussion with the FDA leading... Read more


Intensity Therapeutics to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety 50% fewer grade 3 or higher Adverse Events were observed in the INT230-6 cohort compared to the Standard of Care ("SOC") neoadjuvant chemotherapy alone cohort. Poster PS4-10-15 Describes An Overview of a Potential Phase 3 Clinical Study Design with INT230-6 plus standard... Read more


Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three years Highlighting clinical execution, Roivant announces positive updates to timing guidance across four key programs: Brepocitinib NDA filing in dermatomyositis (DM) now expected in early calendar year 2026; commercial preparation underway with launch expected early in calendar year 2027 Brepocitinib Phase... Read more


Plus Therapeutics Expands CNSide Assay Platform to State of California

CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has been granted lab licenses... Read more


Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN® in Texas

CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive... Read more


InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO's Procedure for the Selection of Recommended... Read more


Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy  Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS  Company initiated Phase 1, Part D study to evaluate weekly MC4R agonist RM-718 in patients with PWS  Company to hold conference call on Thursday, December 11 at 8:00 a.m.  BOSTON,... Read more


BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a... Read more


NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseases ZURICH, Dec. 11, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application in China covering a new class of quinazoline, benzothiazine,... Read more


Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO)...

In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer  There were low rates of adverse events attributed to unconjugated payload such as hematological toxicities and diarrhea, and there were no cases of interstitial lung... Read more


Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12) A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026 Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass.,... Read more


Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial  KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and BREADTH Phase 2b trial in asthma on track to initiate in 1Q26  WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule... Read more


AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio

NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property... Read more


AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson’s disease Clear safety profile with no clinically relevant safety issues reported Targets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessments Underlines potential and importance of active immunotherapies in precision medicine for neurodegenerative diseases AC... Read more


Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalation Manageable tolerability across all dose levels Encouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responses Promising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in... Read more


Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025

Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in P... Read more


Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Study did not meet the primary or key secondary endpoint  45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced... Read more


Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology

Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers. Innovation has the potential to improve preclinical research by reducing reliance on animal testing through New Approach Methodologies (NAMs) such as organoids and predictive modeling, enabling new directions and scale in advanced biomedical studies. Partnership underscores Bio-Techne's commitment to drive innovation and accelerate the broad adoption... Read more


IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal M

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the United States SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients... Read more


Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by... Read more


CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing

Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 11, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI, the "Company"), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced that the Company has entered into a convertible note purchase... Read more


Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded... Read more


Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Head of Pipeline BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment... Read more